Is Prevail Therapeutics Inc. (PRVL) a Buy? The Stock Rises Again

The stock of Prevail Therapeutics Inc. (NASDAQ:PRVL) is a huge mover today! The stock increased 8.64% or $0.93 during the last trading session, reaching $11.7. About 58,960 shares traded. Prevail Therapeutics Inc. (NASDAQ:PRVL) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 6 months positive chart setup for the $398.05 million company. It was reported on Sep, 13 by We have $12.29 PT which if reached, will make NASDAQ:PRVL worth $19.90 million more.

Analysts await Prevail Therapeutics Inc. (NASDAQ:PRVL) to report earnings on November, 13. After $-0.58 actual EPS reported by Prevail Therapeutics Inc. for the previous quarter, Wall Street now forecasts -12.07 % EPS growth.

Prevail Therapeutics Inc. (NASDAQ:PRVL) Ratings Coverage

Among 3 analysts covering Prevail Therapeutics Inc. – common stock (NASDAQ:PRVL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Prevail Therapeutics Inc. – common stock has $2500 highest and $1500 lowest target. $20’s average target is 70.94% above currents $11.7 stock price. Prevail Therapeutics Inc. – common stock had 4 analyst reports since July 15, 2019 according to SRatingsIntel.

More notable recent Prevail Therapeutics Inc. (NASDAQ:PRVL) news were published by: which released: “Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation – GlobeNewswire” on July 08, 2019, also with their article: “Prevail Therapeutics Opens Below IPO Price – Benzinga” published on June 20, 2019, published: “Parkinson’s biotech Prevail Therapeutics sets terms for $125 million IPO – Nasdaq” on June 10, 2019. More interesting news about Prevail Therapeutics Inc. (NASDAQ:PRVL) were released by: and their article: “Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference – Nasdaq” published on September 04, 2019 as well as‘s news article titled: “Health Care Sector Update for 07/08/2019: SGMO, PFE, ITCI, PRVL, JNJ, ABT, MRK, AMGN – Nasdaq” with publication date: July 08, 2019.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV gene therapies for patients with devastating neurodegenerative diseases. The company has market cap of $398.05 million. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It currently has negative earnings. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.